Pharmamarketeer

Theravance Biopharma begins phase 3 study of Ampreloxetine to treat symptomatic neurogenic orthostatic hypotension

Theravance Biopharma, announced dosing of the first patient in a registrational phase 3 clinical trial of ampreloxetine (TD─9855) in patients with symptomatic neurogenic orthostatic hypotension (nOH).

Medhc-fases-banner
Advertentie(s)